Literature DB >> 10741693

Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.

J Mendelsohn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10741693

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  29 in total

Review 1.  Selection and characterization of cell binding and internalizing phage antibodies.

Authors:  Yu Zhou; Lequn Zhao; James D Marks
Journal:  Arch Biochem Biophys       Date:  2012-05-22       Impact factor: 4.013

2.  The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.

Authors:  Yong-Feng Yu; Zhi-Wei Chen; Zi-Ming Li; Zong-Hai Li; Shun Lu
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

Review 3.  The role of the epidermal growth factor receptor in breast cancer.

Authors:  Samuel K Chan; Mark E Hill; William J Gullick
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

Review 4.  EGF receptors as a target for cancer therapy.

Authors:  John Mendelsohn
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

5.  Recombinant chimeric antibody hCAb as a novel anti-human colorectal carcinoma agent.

Authors:  Hua Xiong; Ling Li; Qin-Chuan Liang; Hui-Jie Bian; Juan Tang; Qin Zhang; Li Mi; Zhi-Nan Chen
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

Review 6.  Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases.

Authors:  Rakesh Kumar; Aswathy Mary Paul; Ravikumar Amjesh; Bijesh George; M Radhakrishna Pillai
Journal:  Cancer Metastasis Rev       Date:  2020-08-21       Impact factor: 9.264

7.  John Mendelsohn's journey in cancer biology and therapy.

Authors:  Rakesh Kumar
Journal:  Cancer Biol Ther       Date:  2020-01-23       Impact factor: 4.742

Review 8.  Combining chemotherapy and targeted therapies in metastatic colorectal cancer.

Authors:  J Rodriguez; R Zarate; E Bandres; A Viudez; A Chopitea; J García-Foncillas; I Gil-Bazo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

9.  TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status.

Authors:  Marta Herreros-Villanueva; Pilar Muñiz; Carlos García-Girón; Mónica Cavia-Saiz; María J Coma del Corral
Journal:  J Transl Med       Date:  2010-02-10       Impact factor: 5.531

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.